Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November.

  • On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Guggenheim 2 nd Annual Healthcare Conference in Boston, MA.
  • On Wednesday November 12, 2025, at 1:20 PM EST, Aclaris' President and Chief Operating Officer Dr. Hugh Davis and other members of Aclaris' senior leadership team will participate in a fireside chat during the Stifel 2025 Healthcare Conference in New York, NY.
  • On Monday November 17, 2025, at 2:00 PM GMT (9:00 AM EST), Dr. Walker will participate in a fireside chat during the Jefferies Global Healthcare Conference in London, UK.

Live and archived webcasts of these events will be accessible on the Events page of https://www.aclaristx.com/ . The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ACRS
The Conversation (0)
Skyharbour Announces Participation in Red Cloud's 2025 Fall Mining Showcase in Toronto

Skyharbour Announces Participation in Red Cloud's 2025 Fall Mining Showcase in Toronto

Skyharbour Resources Ltd. (TSX-V: SYH ) (OTCQX: SYHBF ) (Frankfurt: SC1P ) (the "Company") is pleased to announce that the Company will be presenting at Red Cloud's Fall Mining Showcase 2025. The annual conference will be hosted in-person, at the Sheraton Centre Toronto Hotel from November 4-5,... Keep Reading...
Smackover Lithium Receives Key Final Integration Approval from the Arkansas Oil and Gas Commission for South West Arkansas Project

Smackover Lithium Receives Key Final Integration Approval from the Arkansas Oil and Gas Commission for South West Arkansas Project

Smackover Lithium, a 55:45 owned Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV: SLI) (NYSE.A: SLI) and Equinor ("Equinor"), is pleased to announce unanimous approval from the Arkansas Oil and Gas Commission ("AOGC") for its Integration Application... Keep Reading...
Surface Metals Inc. Provides Corporate Update: Gold's 2025 Rally Amplifies Cimarron Gold Project Potential and Strengthens Strategic Position

Surface Metals Inc. Provides Corporate Update: Gold's 2025 Rally Amplifies Cimarron Gold Project Potential and Strengthens Strategic Position

Surface Metals Inc. (CSE: SUR,OTC:SURMF) (OTCQB: SURMF) (the "Company", or "Surface Metals") is pleased to provide a corporate update as gold prices have reached all-time highs in 2025 and the Company advances its portfolio of gold and lithium assets in North America."Gold is reaffirming its... Keep Reading...
Standard Uranium Closes Final Tranche of Private Placement

Standard Uranium Closes Final Tranche of Private Placement

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce that it has closed the final tranche (the "Final Tranche") of its non-brokered private placement (the "Offering") for gross proceeds of $1,513,500. When combined... Keep Reading...
Providence Gold Mines Inc. Acquires Additional Land Position at the La Dama de Oro Gold

Providence Gold Mines Inc. Acquires Additional Land Position at the La Dama de Oro Gold

(TheNewswire) VANCOUVER TheNewswire - October 28, 2025 - Providence Gold Mines Inc. ("Providence" or the "Company ) (TSXV: PHD,OTC:PRRVF) (OTC-PINKS: PRRVF) is very pleased to announce that the Company has staked an additional 100 aces of BLM land are contiguous and parallel to the existing La... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News